Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study

Trastuzumab is the backbone of HER2-positive early breast cancer (eBC) and metastatic breast cancer (mBC) treatment, but limited data exist as to re-treatment in relapsed patients. In this prospective, single arm, multicenter trial, we assessed efficacy and safety of trastuzumab and taxane combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Binghe, Hu, Xichun, Zheng, Hong, Wang, Xiaojia, Zhang, Qingyuan, Cui, Shude, Liu, Donggeng, Liao, Ning, Luo, Rongcheng, Sun, Qiang, Yu, Shiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226610/
https://www.ncbi.nlm.nih.gov/pubmed/27276706
http://dx.doi.org/10.18632/oncotarget.9331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226610/
https://www.ncbi.nlm.nih.gov/pubmed/27276706
http://dx.doi.org/10.18632/oncotarget.9331

Ejemplares similares